Hannah M Linden

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study
    Hannah M Linden
    Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA
    Cancer Nurs 30:261-9. 2007
  2. doi request reprint Novel methods and tracers for breast cancer imaging
    Hannah M Linden
    Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    Semin Nucl Med 43:324-9. 2013
  3. pmc Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer
    Hannah M Linden
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 17:4799-805. 2011
  4. ncbi request reprint Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Hannah M Linden
    Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA
    Clin Cancer Res 12:5608-10. 2006
  5. ncbi request reprint Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
    Hannah M Linden
    Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    J Clin Oncol 24:2793-9. 2006
  6. pmc Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
  7. pmc PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake
    Lisa K Dunnwald
    Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:2400-9. 2011
  8. ncbi request reprint Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
  9. pmc Quantitative assessment of dynamic PET imaging data in cancer imaging
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Magn Reson Imaging 30:1203-15. 2012
  10. pmc Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs
    Brenda F Kurland
    aFred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Trials 10:886-95. 2013

Detail Information

Publications31

  1. pmc Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study
    Hannah M Linden
    Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA
    Cancer Nurs 30:261-9. 2007
    ..Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant...
  2. doi request reprint Novel methods and tracers for breast cancer imaging
    Hannah M Linden
    Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    Semin Nucl Med 43:324-9. 2013
    ....
  3. pmc Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer
    Hannah M Linden
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 17:4799-805. 2011
    ..To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy...
  4. ncbi request reprint Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Hannah M Linden
    Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA
    Clin Cancer Res 12:5608-10. 2006
  5. ncbi request reprint Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
    Hannah M Linden
    Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    J Clin Oncol 24:2793-9. 2006
    ..We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors...
  6. pmc Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
    ..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
  7. pmc PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake
    Lisa K Dunnwald
    Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:2400-9. 2011
    ..Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS)...
  8. ncbi request reprint Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
    ..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
  9. pmc Quantitative assessment of dynamic PET imaging data in cancer imaging
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Magn Reson Imaging 30:1203-15. 2012
    ....
  10. pmc Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs
    Brenda F Kurland
    aFred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Trials 10:886-95. 2013
    ..However, it is often unknown how measurement error and bias in a multicenter trial will differ from that in single-institution studies...
  11. pmc Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer
    Jennifer M Specht
    Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 16:2803-10. 2010
    ..This analysis examines tumor metabolism and perfusion by tumor subtype...
  12. ncbi request reprint Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival
    Lisa K Dunnwald
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    Cancer 103:680-8. 2005
    ..The pathologic response of LABC to presurgical treatment regimens is a prognostic indicator of survival. The authors tested whether MIBI uptake posttherapy predicted survival...
  13. ncbi request reprint Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003
    ..To characterize in vivo tumor biology in patients with LABC, we performed serial measurements of blood flow and glucose metabolism in LABC patients over the course of neoadjuvant chemotherapy and compared measurements with response...
  14. ncbi request reprint 18F-Fluoroestradiol
    Lavanya Sundararajan
    Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA
    Semin Nucl Med 37:470-6. 2007
    ..Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight...
  15. pmc Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
    EJNMMI Res 2:34. 2012
    ..Our study was designed to test for an early decline in FDG uptake in response to AI or T and to examine association with Ki-67 measures of early response...
  16. pmc Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer
    Lanell M Peterson
    Department of Radiology, University of Washington Medical Center, Seattle, WA 98195, USA
    Nucl Med Biol 38:969-78. 2011
    ..Assessment of factors that could affect the quantitative level of FES uptake is important as part of the validation of FES PET for evaluating regional ER expression in breast cancer...
  17. pmc Effect of 18F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer
    Kristen A Wangerin
    Department of Bioengineering, University of Washington, Seattle, Washington
    Tomography 1:53-60. 2015
    ..These results imply that delayed PET imaging may reveal low-conspicuity lesions that would have otherwise gone undetected...
  18. pmc A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)
    Lanell M Peterson
    Radiology Nuclear Medicine, University of Washington Medical Center Seattle Cancer Care Alliance, Seattle, WA, USA
    Mol Imaging Biol 16:431-40. 2014
    ..16α-[(18)F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit...
  19. pmc Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New
    Eunpi Cho
    Department of Medicine, University of Washington, Seattle, WA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
    Clin Breast Cancer 15:e277-85. 2015
    ....
  20. pmc Challenges in clinical studies with multiple imaging probes
    Kenneth A Krohn
    Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 34:879-85. 2007
    ..The purpose of this article is to promote a critical discussion within the molecular imaging community because our future value to the overall biomedical community will be in supporting better treatment outcomes rather than in detection...
  21. doi request reprint Tumor receptor imaging
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
    J Nucl Med 49:149S-63S. 2008
    ....
  22. pmc Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials
    Robert K Doot
    Department of Radiology, University of Washington, Seattle, WA, USA Seattle Cancer Care Alliance, Seattle, WA, USA
    Magn Reson Imaging 30:1291-300. 2012
    ..These methods should be developed and implemented in multicenter clinical trials employing quantitative PET imaging of patients...
  23. ncbi request reprint Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)
    Hannah M Linden
    Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 25:656-61. 2007
    ....
  24. ncbi request reprint Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
    Nina Oestreicher
    University of Washington, Seattle, Washington, USA
    Genet Med 7:380-9. 2005
    ..However, the outcomes associated with gene expression profiling are not clear, and guidelines for the appropriate use of genomic technologies have not been established...
  25. pmc Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials
    Darrin W Byrd
    Department of Radiology, University of Washington, Seattle, Washington
    Tomography 2:353-360. 2016
    ..We conclude that these biases cannot be assumed constant over time. The kits provide a robust method to monitor PET scanner and dose calibrator biases, and resulting biases in standardized uptake values...
  26. ncbi request reprint Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment
    Joann G Elmore
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104 2499, USA
    Med Care 43:141-8. 2005
    ..Recent studies suggest differences in quality and timeliness of care received may be major contributing sources to the racial disparity in breast cancer detection and related outcomes...
  27. ncbi request reprint Myalgias and arthralgias associated with paclitaxel
    Julie A Garrison
    Department of Pharmacy, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Oncology (Williston Park) 17:271-7; discussion 281-2, 286-8. 2003
    ....
  28. pmc The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?
    Eunpi Cho
    Department of Medicine, University of Washington, Seattle, WA, USA
    Breast Cancer Res Treat 149:743-9. 2015
    ..For patients with TNBC, prognosis is guarded following SRS, and there is an urgent need to develop more effective treatment strategies...
  29. ncbi request reprint An ounce of prevention or a pound of cure? Investing to improve breast cancer outcomes for African American women
    Hannah M Linden
    J Clin Oncol 22:2517-8. 2004
  30. ncbi request reprint The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma
    Nina Oestreicher
    Division of Research, Kaiser Permanente, Oakland, California 94612, USA
    Cancer 104:2054-62. 2005
    ..The objective of the current study was to evaluate the direct medical cost of adjuvant chemotherapy in women with early-stage breast carcinoma...
  31. ncbi request reprint Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network Symposium
    Karen Antman
    Columbia University, New York City, NY, USA
    Breast Cancer Res Treat 75:269-80. 2002
    ..The Avon Foundation funded this symposium to bring together interested investigators to share programmatic experiences, data and innovative approaches to the problem...